N@N

MNOV, GLDD, TA, SSRX, ARAY, MITI Are Seasonally Ripe To Go Down In the Next Five Weeks

February 7, 2012 / M2 PRESSWIRE / BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of MEDICINOVA INC (NASDAQ:MNOV), GREAT LAKES DREDGE & DOCK CORPORATION (NASDAQ:GLDD), TRAVELCENTERS OF AMERICA LLC (AMEX:TA), 3SBIO INC-ADR (NASDAQ:SSRX), ACCURAY INC (NASDAQ:ARAY), Micromet Inc (NASDAQ:MITI) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: http://www.squeezetrigger.com/services/strat/mh.php

The following stocks are expected to go Down:

     Symbol     Company                             Expected Return     Odds                    By The Following Date
     MNOV       MEDICINOVA INC                      -2.62%              100.00% (5 of 5)        Thursday, February 9th 2012
     GLDD       GREAT LAKES DREDGE & DOCK CORPORATION     -11.06%             100.00% (5 of 5)        Friday, March 16th 2012
     TA         TRAVELCENTERS OF AMERICA LLC        -18.33%             100.00% (5 of 5)        Friday, March 2nd 2012
     SSRX       3SBIO INC-ADR                       -1.14%              100.00% (5 of 5)        Wednesday, February 8th 2012
     ARAY       ACCURAY INC                         -14.38%             100.00% (5 of 5)        Wednesday, March 21st 2012
     MITI       Micromet Inc                        -7.80%              100.00% (8 of 8)        Tuesday, February 21st 2012

MEDICINOVA INC (NASDAQ:MNOV) - MediciNova, Inc., a biopharmaceutical company, engages in the acquisition and development of small molecule therapeutics for the treatment of diseases with unmet medical needs principally in the United States. The companys development pipeline includes programs that are in clinical development for the treatment of asthma, acute exacerbations of asthma, multiple sclerosis, central nervous system disorders, interstitial cystitis, solid tumor cancers, generalized anxiety disorder/insomnia, preterm labor, and urinary incontinence. Its principal product development programs consist of MN-221, which completed Phase II clinical trial for the treatment of acute exacerbations of asthma, and completed Phase Ib clinical trial for the treatment of chronic obstructive pulmonary disease; MN-166 that has completed Phase II clinical trial for the treatment of multiple sclerosis; and AV411, which has advanced through multiple Phase I and IIa clinical trials for the treatment of central nervous system disorders. The companys other product development programs include MN-001, which completed Phase II/III clinical trial for the treatment of interstitial cystitis and an oral dosing formulation prototype for the treatment of bronchial asthma; MN-029 that completed Phase I clinical trial for the treatment of solid tumors; MN-305, which completed Phase II/III clinical trial for the treatment of generalized anxiety disorder and Phase II clinical trial for the treatment of insomnia; MN-221 that completed a Phase I clinical trial for the treatment of preterm labor; and MN-246, a Phase I clinical trial completed product for the treatment of urinary incontinence. Its preclinical development products comprise MN-447 and MN-462 for the treatment of thrombotic disorders. The company was founded in 2000 and is headquartered in San Diego, California.

GREAT LAKES DREDGE & DOCK CORPORATION (NASDAQ:GLDD) - Great Lakes Dredge & Dock Corporation engages in the business of marine construction, primarily dredging, and commercial and industrial demolition principally in the east, west, and Gulf Coasts of the United States. It operates in two segments, Dredging and Demolition. The Dredging segment involves in capital dredging projects primarily consisting of port expansion projects, land reclamations, trench digging for pipelines, channel deepening, tunnels and cables, and other dredging related to the construction of breakwaters, jetties, canals, and other marine structures; maintenance dredging that comprises the re-dredging of previously deepened waterways and harbors to remove silt, sand, and other accumulated sediments; and beach nourishment projects, which involve moving sand from the ocean floor to shoreline locations. The Demolition segment provides commercial and industrial demolition services. This segment engages in exterior demolition that comprises the dismantling and demolition of structures and foundations; and interior demolition, which involves removing specific structures within a building. It also engages in site development and the removal of asbestos and other hazardous materials. The company serves federal, state, and local governments; foreign governments; domestic and foreign private concerns, such as utilities and oil companies; general contractors; corporations that commission projects; and nonprofit institutions, such as universities and hospitals, and municipal agencies. As of December 31, 2009, Great Lakes Dredge & Dock Corporation had a fleet of 26 dredges, including 10 deployed internationally; 22 material transportation barges; 2 drillboats; and various other specialized support vessels. It was formerly known as Lydon & Drews Partnership and changed its name to Great Lakes Dredge & Dock Corporation in 1905. The company was founded in 1890 and is based in Oak Brook, Illinois.

TRAVELCENTERS OF AMERICA LLC (AMEX:TA) - TravelCenters of America LLC, together with its subsidiaries, operates and franchises travel centers primarily along the United States interstate highway system. It offers diesel fuel and gasoline; operates full service restaurants under the Iron Skillet, Country Pride, Buckhorn Family Restaurants, and Fork in the Road brand names; and operates quick serve restaurants primarily under the Arby's, Burger King, Pizza Hut, Popeye's Chicken & Biscuits, Starbuck's Coffee, Subway, and Taco Bell brand names. The company also operates truck repair and maintenance shops, which offer maintenance and emergency repair, and road services, ranging from basic services, such as oil changes and tire repair to specialty services, including diagnostics and repair of air conditioning, air brakes, and electrical systems; and travel and convenience stores that provide packaged food and snack items, beverages, non-prescription drug and beauty supplies, batteries, automobile accessories, and music and video products, as well as laundry supplies, clothing, and truck accessories. In addition, it provides truck drivers with access to business services, including an information center where drivers can send and receive faxes, overnight mail, and other communications; and a banking desk where drivers can cash checks and receive funds transfers from fleet operators, as well as offers wi-fi Internet access, a video game room, a laundry area, private showers, a theater or television room, and casino gaming. The companys customers comprise long haul trucking fleets and their drivers, independent truck drivers, and motorists. As of December 31, 2009, its business included 233 travel centers under the TravelCenters of America and Petro brand names in the United States and the province of Ontario, Canada. The company was founded in 1992 and is based in Westlake, Ohio.

3SBIO INC-ADR (NASDAQ:SSRX) - 3SBio Inc., a biotechnology company, engages in the research, development, manufacture, and distribution of pharmaceutical products in the Peoples Republic of China. Its products include EPIAO, an injectable recombinant human erythropoietin to stimulate the production of red blood cells in patients with anemia and to reduce the need for blood transfusions; and TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombocytopenia. The company also offers Intefen, a recombinant interferon alpha-2a product for the treatment of carcinoma of the lymphatic or hematopoietic system and viral infectious diseases; Inleusin, a recombinant human IL-2 product to treat renal cell carcinoma, metastatic melanoma, and thoratic fluid build-up caused by cancer and tuberculosis; and Iron Sucrose Supplement for treating anemia associated with iron deficiency, as well as for patients with end-stage renal disease requiring iron replacement therapy. In addition, its product pipeline comprises a high dosage EPIAO; NuPIAO, a second-generation EPIAO; TPIAO to treat idiopathic thrombocytopenic purpura; NuLeusin for metastatic melanoma and metastatic renal cell carcinoma; human papilloma virus vaccine for the prevention of cervical cancer; and an anti-TNF monoclonal antibody product candidate for treating rheumatoid arthritis, psoriasis, and other inflammatory diseases. Further, the companys product pipeline includes Feraheme, an in-licensed intravenous iron replacement therapeutic agent used to treat iron deficiency anemia in chronic kidney disease patients and in patients requiring hemodialysis; and Nephoxil, an iron-based phosphate binder for the treatment of hyperphosphatemia in patients with ESRD. It sells its products directly, as well as through its network of distributors to various healthcare providers, including hospitals, clinics, and dialysis centers. The company was founded in 1993 and is headquartered in Shenyang, the Peoples Republic of China.

ACCURAY INC (NASDAQ:ARAY) - Accuray Incorporated designs, develops, and sells the CyberKnife system, an image-guided robotic radiosurgery system used for the treatment of solid tumors. The CyberKnife system combines continuous image-guidance technology with a compact linear accelerator to deliver high doses of radiation to a tumor from different directions. It tracks, detects, and corrects for tumor and patient movement in real-time during the treatment. The CyberKnife systems components and technologies include compact X-band linear accelerator, which generates the radiation to destroy the tumor; robotic manipulator that allows doses of radiation to be delivered from any direction and position; real-time image-guidance system to continuously monitor and correct for patient and tumor movements; X-ray sources to generate X-ray images to determine the location of bony landmarks or implanted fiducials; and image detectors to capture high-resolution anatomical images. The company markets its product through a direct sales force in the United States and a combination of direct sales personnel and distributors internationally. Accuray Incorporated was incorporated in 1990 and is based in Sunnyvale, California.

Micromet Inc (NASDAQ:MITI) - Micromet Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of antibodies for the treatment of cancer, inflammation, and autoimmune diseases. Its product development pipeline includes novel antibodies generated with its proprietary BiTE antibody platform, as well as conventional monoclonal antibodies. The companys lead product MT103 is in Phase II clinical trial for the treatment of acute lymphoblastic leukemia, as well as in Phase I trial for non-Hodgkins lymphoma. Its Phase II trial product also includes MT201 for solid tumors; and Phase I trial products comprise MT110 and MT293 for solid tumors, and MT203 for the treatment of inflammatory diseases. The companys products in preclinical stage include MT111 to treat solid tumors; BiTE antibody for acute myelogenic lymphoma and solid tumors; MT228 for melanoma; and MT204 for the treatment of inflammatory diseases, including rheumatoid arthritis, asthma, acute transplant rejection, uveitis, psoriasis, and multiple sclerosis. It has license agreements and collaborations with Biovation Limited; Enzon Pharmaceuticals, Inc.; MedImmune LLC; Bayer Schering Pharma AG; TRACON Pharmaceuticals, Inc.; Nycomed A/S; Morphotek, Inc.; Sanofi-Aventis; and Boehringer Ingelheim. The company is headquartered in Bethesda, Maryland.

SqueezeTrigger.com has built a massive database that collects, analyzes and publishes multiple proprietary trading strategies that predict price moves in stocks, commodities and currencies. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of each of the strategies highlighted. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com

www.squeezetrigger.com monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO.

INVESTMENTS & TRADING

SqueezeTrigger -- 25 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

About SQUEEZETRIGGER.COM

WWW.SQUEEZETRIGGER.COM is a service designed to help bonafide shareholders of publicly traded US companies fight short selling. SqueezeTrigger.com has built a proprietary database that uses Threshold list feeds and short sale time and sale data from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short trades.

SQUEEZETRIGGER.COM has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2.5 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha'a"s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by SQUEEZETRIGGER.COM, based upon information believed to be reliable. The information contained herein is not guaranteed by SQUEEZETRIGGER.COM to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion.

Occassionally companies pay $995.00 to purchase data for information provided in reports issued by BUYINS.NET, a company affiliated with SQUEEZETRIGGER.COM. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SQUEEZETRIGGER.COM is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. SQUEEZETRIGGER.COM will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

SQUEEZETRIGGER.COM and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of SQUEEZETRIGGER.COM, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.

By visiting SQUEEZETRIGGER.COM or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. Global Automated Trading Systems, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to SQUEEZETRIGGER.COM and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.

Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. SQUEEZETRIGGER.COM does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. SQUEEZETRIGGER.COM places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SQUEEZETRIGGER.COM undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

Contact: Thomas Ronk, CEO www.squeezetrigger.com +1-800-715-9999 Tom@squeezetrigger.com

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641